Prothena Co. plc (NASDAQ:PRTA) CFO Tran Nguyen Sells 10,000 Shares

Posted by Matthew Steigler on Mar 18th, 2023

Prothena Co. plc (NASDAQ:PRTA – Get Rating) CFO Tran Nguyen sold 10,000 shares of Prothena stock in a transaction dated Wednesday, March 15th. The shares were sold at an average price of $48.43, for a total value of $484,300.00. Following the sale, the chief financial officer now owns 3,200 shares of the company’s stock, valued at approximately $154,976. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Tran Nguyen also recently made the following trade(s):

On Wednesday, February 15th, Tran Nguyen sold 10,000 shares of Prothena stock. The shares were sold at an average price of $53.34, for a total value of $533,400.00.
On Wednesday, January 18th, Tran Nguyen sold 10,000 shares of Prothena stock. The stock was sold at an average price of $55.53, for a total value of $555,300.00.
On Wednesday, December 21st, Tran Nguyen sold 10,000 shares of Prothena stock. The stock was sold at an average price of $58.97, for a total value of $589,700.00.

Prothena Price Performance

Prothena stock traded down $0.70 during trading hours on Friday, reaching $48.27. The company had a trading volume of 1,079,819 shares, compared to its average volume of 503,695. The company has a 50-day moving average price of $53.84 and a 200 day moving average price of $52.49. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -19.23 and a beta of 0.41. Prothena Co. plc has a 12-month low of $21.06 and a 12-month high of $66.47.

Prothena (NASDAQ:PRTA – Get Rating) last posted its earnings results on Thursday, February 23rd. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.76. Prothena had a negative return on equity of 24.98% and a negative net margin of 216.95%. The firm had revenue of $49.90 million for the quarter, compared to analysts’ expectations of $29.14 million. During the same period in the previous year, the firm earned ($0.71) earnings per share. The business’s revenue was up 4058.3% compared to the same quarter last year. As a group, research analysts expect that Prothena Co. plc will post -3.7 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently weighed in on PRTA shares. Piper Sandler started coverage on Prothena in a research report on Friday, January 27th. They issued an “overweight” rating and a $94.00 target price for the company. StockNews.com started coverage on Prothena in a research report on Thursday. They issued a “hold” rating for the company. Citigroup dropped their target price on Prothena from $76.00 to $72.00 and set a “buy” rating for the company in a research report on Monday, February 27th. Cantor Fitzgerald boosted their target price on Prothena from $91.00 to $98.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 21st. Finally, HC Wainwright restated a “buy” rating and issued a $75.00 target price on shares of Prothena in a research report on Friday, February 24th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $82.50.

Hedge Funds Weigh In On Prothena

Several hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC increased its stake in shares of Prothena by 3.0% during the third quarter. ProShare Advisors LLC now owns 7,858 shares of the biotechnology company’s stock valued at $476,000 after buying an additional 228 shares during the period. Arizona State Retirement System increased its stake in shares of Prothena by 4.1% during the fourth quarter. Arizona State Retirement System now owns 9,268 shares of the biotechnology company’s stock valued at $558,000 after buying an additional 364 shares during the period. Credit Suisse AG increased its stake in shares of Prothena by 1.3% during the second quarter. Credit Suisse AG now owns 27,724 shares of the biotechnology company’s stock valued at $753,000 after buying an additional 369 shares during the period. Amalgamated Bank increased its stake in shares of Prothena by 7.1% during the fourth quarter. Amalgamated Bank now owns 6,126 shares of the biotechnology company’s stock valued at $369,000 after buying an additional 406 shares during the period. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of Prothena during the third quarter valued at approximately $27,000. 91.72% of the stock is owned by hedge funds and other institutional investors.

Prothena Company Profile

(Get Rating)

Prothena Corp. Plc is a clinical-stage neuroscience company. It focuses on the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases.